The company’s managing director Dr Richard Hopkins told investors at this week’s Proactive CEO Sessions in Sydney and Melbourne that the company is well placed to service a rapidly growing global market.
READ: Zelda Therapeutics to use Federal Government RD tax rebate of $769,000 to drive clinical trials
He said the company was building a portfolio of clinically validated assets which presented multiple revenue opportunities to license and generate milestone and royalty payments.
This strategy was well advanced because the company had a singular focus on clinical validation to address key unmet needs.
Among the interesting medicinal cannabis market dynamics outlined were:
- Medicinal cannabis is legal in more than 34 countries and in 35 US states;
- Only around 1% of the population in